EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Estimating lead time and overdiagnosis in cancer screening programmes: the MOCCI method

Bor Vratanar iD, Maja Pohar Perme

International Journal of Epidemiology · 2026

DOI: 10.1093/ije/dyag167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Epidemiology, 2026. Verfasst von Bor Vratanar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Biostatistics and Medical Informatics, University of Ljubljana, Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Early Detection of Cancer, Overdiagnosis, Breast Neoplasms, Mass Screening. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Slovenian Research Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer screening enables earlier cancer diagnosis and treatment. The interval between cancer diagnosis by screening and the symptomatic detection in the absence of screening is termed lead time. If a patient’s tumour, detected by screening, would never surface clinically, the patient is considered overdiagnosed. Estimating these quantities is crucial for evaluating cancer screening programmes. Development We developed MOCCI (Minimizing Observed and Counterfactual Cancer Incidence), a novel parametric method for estimating the lead time distribution. MOCCI compares age- and calendar-stratified cancer incidence between individuals invited to screening and those not invited and estimates the lead time distribution that minimizes the incidence difference between the two groups. The probability of overdiagnosis is then estimated by comparing the model-predicted lead time with the time to death from other causes. Application In an application to the Slovenian breast cancer screening programme, we estimated that 30% (95% confidence interval [CI], 20% to 39%) of screen-detected cases were non-progressive and 33% (95% CI, 25% to 43%) were overdiagnosed; assuming an exponential lead time distribution for progressive cancers, the mean lead time was 1.8 years (95% CI, 1.3 to 2.9).

Conclusions

This study proposes a new method for estimating lead time and overdiagnosis. The proposed method (a) can accommodate various lead time distributions, (b) yields a lead time distribution that is aligned with the observed excess incidence arising from screening, and (c) enables the separation of different sources of overdiagnosis. The method provides stable estimates when sample sizes are large and the assumed lead time model is simple.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Early Detection of CancerOverdiagnosisBreast NeoplasmsMass ScreeningMedical OveruseHumansFemaleIncidenceSloveniaMiddle AgedTime FactorsAged

Stichwörter der Autor:innen

causal inferencecounterfactualdeconvolutionincidencelead timeoverdiagnosis

Autor:innen und Institutionen

  • Institute for Biostatistics and Medical Informatics, University of Ljubljana, Ljubljana, Slovenia.

ORCID-Profile: Bor Vratanar

Förderung

  • the Slovenian Research Agency

Zitieren

APA

Vratanar, B., & Pohar Perme, M. (2026). Estimating lead time and overdiagnosis in cancer screening programmes: the MOCCI method. International Journal of Epidemiology. https://doi.org/10.1093/ije/dyag167

Vancouver

Vratanar B, Pohar Perme M. Estimating lead time and overdiagnosis in cancer screening programmes: the MOCCI method. International Journal of Epidemiology. 2026. doi:10.1093/ije/dyag167

BibTeX
@article{Vratanar2026,
  author = {Vratanar, Bor and Pohar Perme, Maja},
  title = {Estimating lead time and overdiagnosis in cancer screening programmes: the MOCCI method},
  journal = {International Journal of Epidemiology},
  year = {2026},
  doi = {10.1093/ije/dyag167}
}
Kostenlos starten →